Modulators of Androgen Synthesis

Abstract

The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.

1 . A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and from 0.01 mg/kg/day to 0.5 mg/kg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
 wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid.   
     
     
         2 . The method according to  claim 1 , the therapeutically effective amount of risperidone is from 0.1 mg/day to 20 mg/day. 
     
     
         3 . The method according to  claim 1 , wherein the therapeutically effective amount of risperidone is from 0.01 mg/kg/day to 1 mg/kg/day. 
     
     
         4 . The method according to  claim 1 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof. 
     
     
         5 . The method according to  claim 1 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously. 
     
     
         6 . The method according to  claim 1 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition. 
     
     
         7 . A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual from 0.01 mg/kg/day to 0.5 mg/kg/day of a risperidone and from 0.01 mg/kg/day to 0.5 mg/kg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
 wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid.   
     
     
         8 . The method according to  claim 7 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof. 
     
     
         9 . The method according to  claim 7 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously. 
     
     
         10 . The method according to  claim 7 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition. 
     
     
         11 . A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and from 0.1 mg/day to 20 mg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
 wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid.   
     
     
         12 . The method according to  claim 11 , the therapeutically effective amount of risperidone is from 0.1 mg/day to 20 mg/day. 
     
     
         13 . The method according to  claim 11 , wherein the therapeutically effective amount of risperidone is from 0.01 mg/kg/day to 0.5 mg/kg/day. 
     
     
         14 . The method according to  claim 11 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof. 
     
     
         15 . The method according to  claim 11 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously. 
     
     
         16 . The method according to  claim 11 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.